Cessation of nucleos(t)ide analogue treatment after HBeAg seroconversion is associated with a 4-fold increased risk of relapse in cirrhotic compared to non-cirrhotic patients

Authors
Publication date
1 October 2017
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Open Repository and Bibliography - Liège

    redirect
    oaioai:orbi.ulg.ac.be:2268/215632
    Last time updated on 21/11/2017